Mineralys Therapeutics, Inc. (MLYS) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.97B USD. 52-week range 21.46 to 47.65 USD. Data as of 2026-10-09.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name ...